Evidence map›Paper›PMID 40942138›Full record

ArticleMolecules (Basel, Switzerland)2025

Notoginsenoside R1, a Metabolite from

Muneerah Al-Musailem, Willias Masocha, Altaf Al-Romaiyan

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Muneerah Al-MusailemMaster of Science in Pharmaceutical Sciences Program, College of Pharmacy, Kuwait University, Safat 13110, Kuwait.
Willias MasochaDepartment of Pharmacology & Therapeutics, College of Pharmacy, Kuwait University, Safat 13110, Kuwait.ORCID 0000-0003-3132-5935
Altaf Al-RomaiyanDepartment of Pharmacology & Therapeutics, College of Pharmacy, Kuwait University, Safat 13110, Kuwait.

Funding

Kuwait University YP01/24
6 · The paper itself

Abstract

Development of paclitaxel-induced neuropathic pain (PINP) during chemotherapy may lead to paclitaxel discontinuation, potentially compromising effective anticancer therapy. PINP can manifest as allodynia. One recently discovered key factor in paclitaxel-induced mechanical allodynia (PIMA) pathogenesis is the elevated activity of monoacylglycerol lipase (MAGL), an enzyme that metabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG). Thus, inhibiting MAGL serves as a potential analgesic target. Notoginsenoside R1 (NGR1), a metabolite of

Indexed as

GinsenosidesNeuralgiaPaclitaxelPanax notoginsengAnimalsDisease Models, AnimalFemaleHyperalgesiaMiceMice, Inbred BALB CMolecular Docking SimulationMonoacylglycerol LipasesGinsenosidesMonoacylglycerol Lipasesnotoginsenoside R1Paclitaxelmechanical allodyniamonoacylglycerol lipase activitypaclitaxelperipheral neuropathyplant extracttriterpenoid

Identifiers

PMID40942138
PMCPMC12430169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.